Human neural stem cell therapy for the treatment of cervical spinal cord injury (
人类神经干细胞疗法治疗颈脊髓损伤(
基本信息
- 批准号:8503499
- 负责人:
- 金额:$ 226.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-01 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdverse effectsAmericanAnimalsAntibodiesAutonomic DysreflexiaAxonBehavioralBilateralBiological AssayBrainCationsCell TransplantsCellsCervicalCervical spinal cord injuryChestChronicClinicalClinical DataClinical TrialsClinical Trials Data Monitoring CommitteesCognitiveCollaborationsConsultationsContusionsDataData AnalysesDevelopmentDiscriminationEngraftmentEnrollmentEsthesiaExhibitsFeedbackHumanHybridsHyperalgesiaImmunodeficient MouseImmunosuppressionIndividualInjuryLightLocomotor RecoveryModelingMotorMusNeuraxisNeuronal Ceroid-LipofuscinosisNeuronsNeurosurgeonOligodendrogliaOutcome MeasurePatientsPelizaeus-Merzbacher DiseasePerformancePhasePhase I Clinical TrialsPhenotypePopulationPregnancyPrincipal InvestigatorQuality of lifeRattusRecoveryRecovery of FunctionRegulatory AffairsReportingResearch DesignRodent ModelSafetyScientistSensorySiteSpinal cord injurySpinal cord injury patientsStem cell transplantStem cellsTestingTherapeuticThoracic spinal cord structureTimeTouch sensationToxicologyTranslationsTransplantationUniversitiesXenoXenograft procedureallodyniabaseclinical efficacycohortefficacy testingexperiencefetalgain of functionin vivoinjuredmeetingsmigrationmouse modelmyelinationnerve stem cellnervous system transplantationnonhuman primatepre-clinicalprogramssafety studystem cell therapysynaptogenesistherapeutic target
项目摘要
DESCRIPTION (provided by applicant): We previously demonstrated pre-clinical efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) in multiple rodent models of thoracic spinal cord injury (SCI). HuCNS-SC transplanted at 9, 30, and 60 days post-injury (dpi) engraft, survive, migrate, and exhibit predominant differentiation into oligodendrocytes and neurons. Critically, transplanted cells promoted recovery of locomotor function and showed no evidence of allodynia at each of these transplantation times. These data contributed to a Phase I/II SwissMedic trial targeting chronically injured individuals suffering from thoracic SCIs; the first patient received HuCNS-SC in September 2011 at the University of Zurich. Critically, 52% of clinical cases of SCIs occur at the cervical level. Targeting the chronic SCI population yields a much larger subject cohort and advantages for clinical safety and efficacy assessment (e.g. spontaneous recovery is a significant confound acutely). Discrimination of a therapy induced improvement for SCI is dependent, in part, on the spontaneous recovery rate. Spontaneous recovery is highest in acute thoracic subjects, and lowest in chronic cervical subjects. An acute thoracic SCI trial has been estimated to require as many as 225-250 ASIA A subjects and 1,100 ASIA B subjects to detect a moderate effect. In contrast, a chronic cervical SCI trial may require as few as 25 ASIA A subjects, and 50 ASIA B subjects. Further, a small gain of function in the cervical region affords a proportionally greater change in quality of life compared to a similar gain at the thoracic level. We have generated a unilateral cervical SCI model using immunodeficient Rag2g/c mice to optimize xeno-engraftment, and demonstrated that 9 dpi transplantation of HuCNS-SC promotes recovery of locomotor function with no adverse effects, establishing pre-clinical efficacy of HuCNS-SC. The UCI-StemCells Inc. team already has considerable experience in clinical translation using HuCNS-SC and has sought preliminary feedback from the FDA for a cervical SCI indication in the form of a pre-preIND consultation. This proposal is based on our FDA interactions and seeks to expand our current cervical SCI efficacy data to evaluate the intended clinical cell lot of HuCNS-SC for both efficacy and long-term safety/toxicology addressing the following Specific Aims: Aim 1: Establish efficacy and test cell delivery site for the HuCNS-SC CCL in a 9 dpi transplantation unilateral cervical SCI mouse model. Aim 2: Establish efficacy and test cell delivery site for the HuCNS-SC CCL in a 60 dpi transplantation unilateral cervical SCI mouse model. Aim 3: Assess the safety of the HuCNS-SC CCL in a rodent model of autonomic dysreflexia. Aim 4: Establish long-term safety/toxicology of the HuCNS-SC CCL in the established unilateral cervical SCI mouse model. Aim 5: If dictated by the FDA in a pre-IND meeting in Year 2, establish efficacy and safety/toxicology for the HuCNS-SC
CCL in a second species (ATN rat), using a hybrid study design and cervical SCI rats receiving supplemental immunosuppression with anti-sialoGM1 antibody treatment. The aims of this project will enable IND application for the use of this HuCNS-SC clinical cell lot for cervical SCI
as a therapeutic target.
描述(由申请人提供):我们之前证明了人类中枢神经系统干细胞(HuCNS-SC)在胸脊髓损伤(SCI)的多种啮齿动物模型中的临床前功效。在损伤后 9、30 和 60 天 (dpi) 移植的 HuCNS-SC 植入、存活、迁移并表现出向少突胶质细胞和神经元的主要分化。重要的是,移植的细胞促进了运动功能的恢复,并且在每个移植时间都没有显示出异常性疼痛的证据。这些数据促成了 SwissMedic 针对患有胸部 SCI 的慢性损伤患者的 I/II 期试验;首例患者于 2011 年 9 月在苏黎世大学接受了 HuCNS-SC 治疗。至关重要的是,52% 的 SCI 临床病例发生在颈部。以慢性 SCI 人群为目标,可以产生更大的受试者群体,并有利于临床安全性和疗效评估(例如,自发恢复是一个严重的混杂因素)。对治疗引起的 SCI 改善的区分部分取决于自发恢复率。急性胸部受试者的自发恢复最高,而慢性颈椎受试者的自发恢复最低。据估计,一项急性胸部 SCI 试验需要多达 225-250 名 ASIA A 受试者和 1,100 名 ASIA B 受试者才能检测到中等效果。相比之下,慢性颈椎 SCI 试验可能只需要 25 名 ASIA A 受试者和 50 名 ASIA B 受试者。此外,与胸部水平的类似功能增益相比,颈部区域的小幅功能增益可带来更大的生活质量变化。我们使用免疫缺陷的 Rag2g/c 小鼠建立了单侧颈椎 SCI 模型来优化异种移植,并证明 HuCNS-SC 的 9 dpi 移植可促进运动功能的恢复,且无不良影响,从而确立了 HuCNS-SC 的临床前疗效。 UCI-StemCells Inc. 团队在使用 HuCNS-SC 进行临床转化方面已经拥有丰富的经验,并以 pre-preIND 咨询的形式寻求 FDA 对宫颈 SCI 适应症的初步反馈。该提案基于我们与 FDA 的互动,旨在扩展我们当前的颈椎 SCI 疗效数据,以评估 HuCNS-SC 的预期临床细胞批次的功效和长期安全性/毒理学,解决以下具体目标: 目标 1:在 9 dpi 移植单侧颈椎 SCI 小鼠模型中建立 HuCNS-SC CCL 的功效和测试细胞递送位点。目标 2:在 60 dpi 移植单侧颈椎 SCI 小鼠模型中建立 HuCNS-SC CCL 的功效并测试细胞递送位点。目标 3:评估 HuCNS-SC CCL 在自主神经反射障碍啮齿动物模型中的安全性。目标 4:在已建立的单侧颈椎 SCI 小鼠模型中建立 HuCNS-SC CCL 的长期安全性/毒理学。目标 5:如果 FDA 在第 2 年的 IND 前会议上提出要求,则确定 HuCNS-SC 的功效和安全性/毒理学
第二种物种(ATN 大鼠)的 CCL,采用混合研究设计,颈椎 SCI 大鼠接受抗 sialoGM1 抗体治疗的补充免疫抑制。该项目的目标是使 HuCNS-SC 临床细胞批用于颈椎 SCI 的 IND 申请成为可能
作为治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aileen J Anderson其他文献
Aileen J Anderson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aileen J Anderson', 18)}}的其他基金
Investigating the role of CD44 and immune-neuro signaling mechanisms in neural stem cell responses after spinal cord injury
研究 CD44 和免疫神经信号传导机制在脊髓损伤后神经干细胞反应中的作用
- 批准号:
10467915 - 财政年份:2022
- 资助金额:
$ 226.44万 - 项目类别:
Investigating the role of CD44 and immune-neuro signaling mechanisms in neural stem cell responses after spinal cord injury
研究 CD44 和免疫神经信号传导机制在脊髓损伤后神经干细胞反应中的作用
- 批准号:
10650327 - 财政年份:2022
- 资助金额:
$ 226.44万 - 项目类别:
Multi-channeled Bridges for Promoting Chronic Spinal Cord Repair
促进慢性脊髓修复的多通道桥
- 批准号:
10249977 - 财政年份:2020
- 资助金额:
$ 226.44万 - 项目类别:
Multi-channeled Bridges for Promoting Chronic Spinal Cord Repair
促进慢性脊髓修复的多通道桥
- 批准号:
10469553 - 财政年份:2020
- 资助金额:
$ 226.44万 - 项目类别:
Multi-channeled Bridges for Promoting Chronic Spinal Cord Repair
促进慢性脊髓修复的多通道桥
- 批准号:
10700124 - 财政年份:2020
- 资助金额:
$ 226.44万 - 项目类别:
Nanoparticle-mediated reprogramming of circulating monocytes and neutrophils to decrease inflammation-mediated damage after trauma
纳米颗粒介导的循环单核细胞和中性粒细胞重编程可减少创伤后炎症介导的损伤
- 批准号:
10212226 - 财政年份:2019
- 资助金额:
$ 226.44万 - 项目类别:
Nanoparticle-mediated reprogramming of circulating monocytes and neutrophils to decrease inflammation-mediated damage after trauma
纳米颗粒介导的循环单核细胞和中性粒细胞重编程可减少创伤后炎症介导的损伤
- 批准号:
10437650 - 财政年份:2019
- 资助金额:
$ 226.44万 - 项目类别:
Nanoparticle-mediated reprogramming of circulating monocytes and neutrophils to decrease inflammation-mediated damage after trauma
纳米颗粒介导的循环单核细胞和中性粒细胞重编程可减少创伤后炎症介导的损伤
- 批准号:
9978712 - 财政年份:2019
- 资助金额:
$ 226.44万 - 项目类别:
Nanoparticle-mediated reprogramming of circulating monocytes and neutrophils to decrease inflammation-mediated damage after trauma
纳米颗粒介导的循环单核细胞和中性粒细胞重编程可减少创伤后炎症介导的损伤
- 批准号:
10669080 - 财政年份:2019
- 资助金额:
$ 226.44万 - 项目类别:
Human neural stem cell therapy for the treatment of cervical spinal cord injury (
人类神经干细胞疗法治疗颈脊髓损伤(
- 批准号:
8727119 - 财政年份:2013
- 资助金额:
$ 226.44万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 226.44万 - 项目类别:
Research Grant